Clinical Advisory Board


Professor Frederik Barkhof, MD, PhD

Professor of Neuroradiology, Dept of Radiology & Nuclear Medicine, VU University Medical Centre (VUmc), Amsterdam, The Netherlands & UCL institutes of Biomedical Engineering and Neurology, London, UK.

Professor Barkhof received his MD from VU University, Amsterdam (NL) in 1988 and defended his PhD thesis in 1992, for which he received the Philips Prize for Radiology (1992) and the Lucien Appel Prize for Neuroradiology (1994). Since 2001 he serves as a full Professor in Neuroradiology at the department of Radiology & Nuclear Medicine at VUmc. He is a senior staff member of the MS Center Amsterdam, and senior consultant of the Alzheimer Center, VUmc. In 2015 he was appointed as full Professor of Neuroradiology at institutes of Biomedical Engineering and Neurology at UCL in London (UK) to translate novel imaging techniques.

Professor Barkhof was the chairman of the Dutch Society of Neuroradiology and the MAGNIMS study group for many years. He is the Scientific Director of the Image Analysis Centre (IAC), involved in analysis of multicentre drug trials. He serves on the Editorial boards of Radiology, Brain, Multiple Sclerosis Journal, Neuroradiology and Neurology.

Professor Barkhof’s research interests focus on childhood white matter disease, on multiple sclerosis (spinal cord MRI, grey matter, atrophy, histopathology correlations), on ageing (white matter lesions and microbleeds) and on dementia (hippocampal atrophy in Alzheimer and functional MR). He (co)authored >850 papers referenced in PubMed, has an H-factor of 102 and is listed among 3000 most influential scientists world-wide by Thompson-Reuters. He is the author of the books “Neuroimaging in Dementia” and “Clinical applications of functional brain MRI”.

Cumulatively, he has received >25 million euro grant money from various national and international funding agencies and performed contract research for all major pharmaceutical companies with cumulative contract value of > 15 million euro. More than 30 PhD students graduated under his supervision and 2 of them have subsequently attained a full professorship.

Dr Jeremy Chataway MA, PhD, FRCP

Consultant Neurologist National Hospital for Neurology and Neurosurgery, Queen Square, University College Foundation NHS Trust and Reader in Neurology, University College London.

Dr Chataway is the clinical lead of the MS group at the NHNN (about 3000 patients) and was a member of the 2014 MS NICE panel. He has a particular interest in clinical trial design and was the Chief Investigator (CI) of the recently reported MS-STAT1 trial in secondary progressive MS, using high dose simvastatin; and is the CI of the currently recruiting MRC/EME MS-SMART trial, again in secondary progressive MS. He sits on the UK MS Society Grant Review Panel for Care and Services Research and UK MS Society Clinical Trials Network Steering Group; and is the Interim Clinical Director of the UCL Comprehensive Clinical Trials Unit. He is keen to facilitate both advanced trial design and implementation.

Dr Robert J. Fox, MD

Staff Neurologist at the Mellen Center for Multiple Sclerosis, Vice-Chair for Research of the Neurological Institute, Cleveland Clinic, and Professor of Medicine (Neurology) at Cleveland Clinic Lerner College of Medicine.

Dr Fox received his medical degree from Johns Hopkins University, neurology training at the University of Pennsylvania, a master’s degree in Clinical Research from Case Western Reserve University, and multiple sclerosis fellowship training at Cleveland Clinic. Dr Fox’s current research interests focus clinical trials in multiple sclerosis, innovative MRI techniques to evaluate tissue recovery after injury and the effects of MS treatments, as well as MS patient decision-making and tolerance to risk. He has published over 200 peer-reviewed papers, book chapters, and books. He serves as an advisor for many clinical trials, including the principal investigator of the NIH-funded SPRINT-MS phase II trial of ibudilast in progressive MS. In addition, he serves as the Managing Director of the NARCOMS MS Patient Registry, which currently follows over 10,000 people with MS. Dr. Fox serves as a member of various advisory and review committees for the National MS Society (USA), International Progressive MS Alliance, National Institutes of Health (USA), the General Advisory Council for the Cleveland Clinic Clinical Research Unit, the Editorial Board of Neurology and Multiple Sclerosis Journal, and as a consultant to the pharmaceutical industry.

Fred D. Lublin, M.D.

Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis.

Dr Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS. He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He was a member of the National MS Society National Board of Directors. He is immediate past Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS, updated in 2014. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS. Dr Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He is a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system. He is a Co-Chief Editor of the journal Multiple Sclerosis and Related Disorders.

Dr Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. Dr Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis.

Professor Tomas Olsson, MD, PhD

Professor of Neurology, Karolinska Institute, Stockholm, Sweden.

Professor Olsson received his MD from University of Linköping, Sweden in 1977 and went on to complete his PhD in Medical Sciences in 1980. Having obtained Specialist in Clinical Neurology in 1984, he currently holds the post of Professor in Neurology at Karolinska Institute, Sweden.

He was Chairman for the Swedish expert committee for Multiple Sclerosis (1997-2002) and is now a member and co-founder of the Swedish Multiple Sclerosis society as well as a member of multiple international MS societies. Prof. Olsson is a board member and co-founder of the European school of Neuroimmunology (ESNI), member of the international scientific board of the international congress of Neuroimmunology (ISNI), executive board member of the international scientific board of the European committee for the treatment of MS (ECTRIMS) and member of the International Multiple Sclerosis Genetics Consortium (IMSGC).

Professor Olssons’s research interests focus on neuroinflammation with focus on multiple sclerosis, genetics, immunology and life style/environmental factors. He has (co)authored 429 original papers published in peer reviewed journals and has an H-index of 82. In 1994 he won the Erik K Fernströms prize for Medical research, in 2012 the K/ F Johansens International Award, Copenhagen and in 2014 the Swedbank's Science Prize.



Professor Simon Pearce MBBS, MD, FRCP

Professor of Endocrinology at Newcastle University, UK.

Professor Pearce qualified in Medicine. He also undertook postgraduate education in endocrinology at the Royal Postgraduate Medical School in Hammersmith and Brigham & Women’s Hospital in Boston. Professor Pearce was first appointed Senior Lecturer in Endocrinology in 2001 at Newcastle University and became Professor in 2007.

Professor Pearce has served on the editorial boards of the Journal of Clinical Endocrinology & Metabolism (2008-2010 and 2013-2016), Endocrinology (2012-2014) and the European Thyroid Journal. He was a member of the British Thyroid Association executive committee between 2006 and 2012 and the European Thyroid Association between 2011 and 2014.

Professor Pearce’s main research area is the treatment for autoimmune thyroid disease, including thyroid eye disease and Addison’s disease. He has published about 130 papers over the last 20 years spanning molecular endocrinology, clinical trials and guideline papers.

Professor George J Kahaly, M.D., Ph.D.

Professor of Medicine and Endocrinology / Metabolism and chief of the endocrine outpatient clinic at the Johannes Gutenberg University Medical Center, Mainz, Germany.

Professor Kahaly directs the Molecular Thyroid Research Laboratory and has authored 241 original papers and reviews, covering clinical and experimental aspects of endocrine autoimmunity, immunogenetics of thyroid and polyglandular autoimmunity, as well as cardiovascular involvement of metabolic disorders. Original papers and reviews have been published in the New England Journal of Medicine, the Journal of Autoimmunity, the Journal of Clinical Endocrinology and Metabolism, the Journal of Nuclear Medicine, Thyroid, Endocrine Reviews, Nature Reviews and Autoimmunity Reviews.

Professor Kahaly is Editor of the Journal of Clinical Endocrinology & Metabolism, official Organ of the American Endocrine Society. In the years 2009-2012, Dr Kahaly served as Associate Editor of the journal THYROID, official journal of the American Thyroid Association (ATA). Prof Kahaly is also member of the Editorial Board of the European Thyroid Journal, official journal of the European Thyroid Association (ETA).

Professor Kahaly served as Treasurer and principle officer of the Executive Committee of the ETA between 2007 and 2016. He currently serves on the Public Health Commit- tee of the ATA. In the years 2012-2015, Prof Kahaly has been active member of the ATA Research Committee, in 2007-2011, of the ATA Finance and Audit Committee, and in 2000-2006 member of the ATA Membership and Publication Committees. Further, Prof Kahaly is the Treasurer of the European Group on Graves’ orbitopathy, official subgroup of the ETA. In the years 2005-2011, he was member of the Executive Committee of the German Thyroid Board.

Professor Chantal Daumerie

Professor emeritus at the Faculty of medicine of the University of Louvain (UCL) and Cliniques Universitaires Saint-Luc.

Professor Daumerie was raised in Brussels, educated at UCL before training in Internal Medicine, in Endocrinology and Nuclear Medicine.

Professor Daumerie obtained a research mandate of the prestigious National Fund for scientific Research to study the influence of Somatostatin on the intestinal absorption of the nutrients.

She has previously served as president of the Thyroid Belgian Club, is head of thyroidology division in Endocrinology at Cliniques Universitaires Saint-Luc in Brussels and is on the board of the European Group of Orbitopathy (EUGOGO). She is an active member of the European Thyroid Association (ETA) and American Thyroid Association (ATA).

She studied the cerebral metabolism in hypothyroidism, participated to international clinical trials (Phase 2) and many academic studies. She is author of more than 60 peer review papers.



Professor Andrew Dick BSc (Hons) MBBS MD FRCP FRCS FRCOphth FMedSci

Professor of Ophthalmology, Bristol Eye Hospital, Bristol, UK
Director of Joint Research for UCL and Moorfields Eye Hospital and Professor of Ophthalmology, Bristol Eye Hospital, Bristol, UK

Professor Dick from University of London, Charing Cross and Westminster Medical School (BSc (hons), MBBS). Andrew undertook MRCP training prior to entering ophthalmology residency and finally lectureship with Professor John Forrester in Aberdeen Scotland to further his clinician-scientist training. He was an MRC Post Doctoral Fellow and then Senior Lecturer at University of Aberdeen until his move to University of Bristol in 2000 as Chair and Professor of Ophthalmology. In 2007 he was elected and awarded the prestigious Fellowship of the Academy of Medical Sciences.

He remains an active researcher with over 200 peer review publications and lead laboratory and clinical research groups and he is currently on the Faculty of the National Institute of Health Biomedical Research Centre at Moorfields Eye Hospital. He was instrumental in developing the infrastructure and research facilitates for the team to deliver opportunity and choice to our patients through research trials as well as ensure management of complex ocular inflammatory disease and surgical vitreoretinal disorders are evidence based are at the forefront.